HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (4- (daunorubicin- N- carbonyl- oxymethyl)phenyl)- O- glucuronyl carbamate

structure in first source

Also Known As:

DNR-GA3; N-(4-(daunorubicin-N-carbonyl-oxymethyl)phenyl)-O-beta-glucuronyl carbamate

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Necrosis 12/01/1998 - "Our data indicate that DNR-GA3 is more effective than DNR and may be especially of use for treatment of tumours with areas of necrosis." 12/01/1998 - "Treatment with DNR-GA3 was also given to mice with larger tumours that would contain more necrosis (mean size 300-950 mm3). "
2.	Ovarian Neoplasms (Ovarian Cancer) 03/15/1999 - "We determined the pharmacokinetics and distribution of DNR-GA3 in nude mice bearing human ovarian cancer xenografts (OVCAR-3, FMa, A2780, and MRI-H-207). " 12/01/1998 - "The anti-tumour effects of DNR-GA3 and DNR were investigated in four different human ovarian cancer xenografts OVCAR-3, FMa, A2780 and MRI-H-207 at a mean tumour size between 100 and 200 mm3. "
3.	Neoplasms (Cancer) 03/15/1999 - "The specific activation of DNR-GA3 by beta-glucuronidase at the tumor site relative to normal organs leads to a more tumor-selective therapy, resulting in greater efficacy without increased toxicity." 03/15/1999 - "The higher area under the curve of DNR in tumor tissue after DNR-GA3 than after DNR itself would be the result of prodrug activation by beta-glucuronidase. " 03/15/1999 - "These results suggested that the prodrug DNR-GA3 was selectively activated by human beta-glucuronidase present in tumor tissue. "

Related Drugs and Biologics

1.	Prodrugs
2.	Glucuronidase

Related Therapies and Procedures

1.	Therapeutics